Radiomedix Inc.

Orano Med

Radiomedixinc.

Aminomedix Inc.

Ebrahim S Delpassand

Izabela Tworowska

Jennifer Sims-Mourtada

Garry E Kiefer

Ali Azhdarinia

Julien Torgue

Amal Saidi

Nilesh Wagh

Federico Rojas-Quijano

Tania A Stallons

Paul Jurek

Sanjay Thamake

David Ranganathan

Jennifer Sims-mourtada

A cancer targeting composition, kit, and method for treatment of cancer cells overexpressing somatostatin receptors is disclosed. The composition includes a radioisotope, a chelator, and a targeting moiety. The chelator includes a nitrogen ring structure including a tetraazacyclododecane, a triazacyclononane, and/or a tetraazabicyclo [6.6.2] hexadecane derivative. The targeting moiety includes a somatostatin receptor targeting peptide. The somatostatin receptor targeting peptide includes an octreotide derivative. The targeting moiety is chelated to the radioisotope by the chelator whereby the cancer cells are targeted for elimination.

Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes

The invention provides D02S derivatives conjugated to monosaccharide ligands directly or through a linker and optionally chelated to a metal, wherein the D02S derivatives having the following structure: wherein R', R&#x2032; are each independently &#x2014;OH or &#x2014;O-alkyl; Ris a hydrogen, a linker, or a ligand; Ris a linker and/or a ligand; and n is an integer from 1 to 10; the linker is an amino acid, a peptide, an amino alcohol, a polyethylylene glycol, an alkyl, an alkenyl, an alkynyl, an azide, an aromatic compound, a carboxylic acid, or an ester, the alkyl, alkenyl, or alkynyl is optionally substituted with an alkyl, a halogen, a nitro group, a hydroxyl group, an amino group, or a carboxyl group; the ligand is a GLUT1 targeting moiety.

Compositions, methods of synthesis and use of carbohydrate targeted agents

The present invention relates to the field of radiochemistry, nuclear imaging, radionuclide therapy and chemical synthesis. More particularly, it concerns a strategy for radiolabeling target ligands. It further concerns methods of using those radiolabeled ligands for imaging, radionuclide therapy and tissue-specific disease imaging.

Compositions for targeted imaging and therapy

Growing community of inventors

Houston, TX, United States of America

Ebrahim S Delpassand